Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sets New 52-Week High - Still a Buy?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) reached a new 52-week high during trading on Thursday . The company traded as high as $8.65 and last traded at $8.56, with a volume of 1029114 shares trading hands. The stock had previously closed at $8.49.

Analysts Set New Price Targets

A number of research analysts recently commented on BAYRY shares. The Goldman Sachs Group upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, June 11th. Wall Street Zen upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Friday, July 18th. Finally, Kepler Capital Markets upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Wednesday, June 11th. One research analyst has rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of "Buy".

Bayer Aktiengesellschaft Stock Performance

The company has a quick ratio of 0.79, a current ratio of 1.25 and a debt-to-equity ratio of 1.07. The stock has a market cap of $33.46 billion, a price-to-earnings ratio of -9.26 and a beta of 0.86. The company's 50-day simple moving average is $7.55 and its 200-day simple moving average is $6.50.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.02. The firm had revenue of $15.27 billion for the quarter, compared to analyst estimates of $13.39 billion. Bayer Aktiengesellschaft had a negative net margin of 7.26% and a positive return on equity of 13.94%. Analysts predict that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.